Core Viewpoint - Aimeike (300896.SZ) announced that its wholly-owned subsidiary, Beijing Nobot Biotechnology Co., Ltd., received the drug registration certificate for Minoxidil topical solution from the National Medical Products Administration [1] Group 1: Product Details - The Minoxidil topical solution is available in two specifications: 2% and 5% [1] - The 2% specification is indicated for the treatment of androgenetic alopecia and alopecia areata [1] - The 5% specification is restricted for use in males only, specifically for treating androgenetic alopecia and alopecia areata [1]

Core Viewpoint - Zhejiang Huahai Pharmaceutical Co., Ltd. has received the drug registration certificate for Carbetocin Injection from the National Medical Products Administration, which is expected to enhance the company's product line and market competitiveness [1][4]. Drug Basic Information - Drug Name: Carbetocin Injection - Dosage Form: Injection - Specification: 5ml: 25mg (calculated as C??H??N?NaO?S·3H?O) - Registration Category: Class 3 Chemical Drug - Approval Number: National Drug Approval Number H20255532 - The drug is approved for domestic production [1][2]. Market Potential - Carbetocin Injection is used for treating bleeding diseases in the urinary system, upper digestive tract, respiratory tract, and gynecology, with significant efficacy in the urinary system. It can also be used for the prevention and treatment of surgical bleeding [2]. - The domestic market sales forecast for Carbetocin Injection in 2024 is approximately RMB 250 million [2]. R&D Investment - The company has invested approximately RMB 7.12 million in the R&D project for Carbetocin Injection [3]. Impact on the Company - The approval of Carbetocin Injection as a Class 3 Chemical Drug is equivalent to passing the consistency evaluation, which enriches the company's product line and positively impacts its operational development [4].

Core Viewpoint - Hendi Pharmaceutical has obtained the drug registration certificate for Ibuprofen suspension from the National Medical Products Administration as of June 2025, and is currently preparing for product launch and sales [1] Company Developments - The company is actively working on the preliminary preparations for the product's market launch following the receipt of the registration certificate [1] - The impact of the product registration on the company's operating performance is not expected to be significant in the short term [1] Market Considerations - Future revenue generation from the product is uncertain due to factors such as non-uniqueness of the product, competition from similar products, and the effectiveness of the company's business promotion and sales scale [1]

Core Viewpoint - The company has received the drug registration certificate for Famotidine injection from the National Medical Products Administration, which enhances its product line and market competitiveness [1] Summary by Relevant Sections - **Product Approval** - The company has obtained the drug registration certificate for Famotidine injection, a medication that works by inhibiting gastric acid secretion and belongs to the H2 receptor antagonist class [1] - **Impact on Product Line** - The approval of Famotidine injection enriches the company's product offerings, contributing to improved market competitiveness [1] - **Financial Impact** - The acquisition of the drug registration certificate is not expected to have a significant impact on the company's recent operating performance [1]

Group 1 - The company Jilin Aodong (000623.SZ) announced that its subsidiary, Jilin Aodong Pharmaceutical Group Yanji Co., Ltd., received a drug registration certificate from the National Medical Products Administration for "Sulfate Terbutaline Nebulization Solution" [1] - The indication for the sulfate terbutaline nebulization solution is to relieve bronchial asthma, chronic bronchitis, emphysema, and other pulmonary diseases associated with bronchospasm [1]

Core Viewpoint - Beijing Fuyuan Pharmaceutical Co., Ltd. has received the drug registration certificate for Amlodipine Besilate and Benazepril Hydrochloride Capsules, which will enhance the company's product line and market competitiveness [1][2]. Drug Registration Certificate Details - The drug is classified as a Class 3 chemical drug and is prescribed for patients whose blood pressure is not adequately controlled by Amlodipine or Benazepril alone [1]. - The drug's specifications include 5mg of Amlodipine Besilate and 10mg of Benazepril Hydrochloride per capsule [1]. - The registration certificate number is 2025S02582, and the drug is categorized as a prescription medication [1]. Market Information - The total sales of Amlodipine Besilate and Benazepril Hydrochloride Capsules in China for 2024 are estimated to be approximately 1.12 billion yuan, with sales in urban public hospitals and county-level public hospitals accounting for 727 million yuan [1]. - Sales from urban community centers and township health clinics are projected to be 167 million yuan, while urban pharmacies and online pharmacies are expected to generate 226 million yuan [1]. Company Impact - The approval of the drug registration certificate is expected to enrich the company's product portfolio and improve its market competitiveness [2].

Core Viewpoint - The company has received approval for the injectable Nicorandil, which is primarily used for treating unstable angina, enhancing its product portfolio in the cardiovascular field [1] Group 1 - The company's wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., has obtained the drug registration certificate for injectable Nicorandil from the National Medical Products Administration [1] - The approval is considered equivalent to passing the consistency evaluation, which will enrich the company's cardiovascular product offerings [1] - This development is expected to strengthen the company's overall market competitiveness in related medication fields and bring positive impacts for future growth [1]

Core Viewpoint - China National Pharmaceutical Group Modern (国药现代) announced that its wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd. (国药容生), has received the drug registration certificate for injectable Nicorandil from the National Medical Products Administration, which is primarily used for treating unstable angina pectoris [1] Group 1 - The approval of the drug registration certificate signifies that the product has passed the consistency evaluation, enhancing the company's product portfolio in the cardiovascular field [1] - This development is expected to strengthen the company's overall market competitiveness in related medication areas [1] - The impact of this approval on the company's current operating performance is not expected to be significant [1]

Core Viewpoint - The company has received drug registration certificates for "Alpha-Lipoic Acid Tablets" and "Bisoprolol Amlodipine Tablets" from the National Medical Products Administration, which will enhance its product line and positively impact its development [1] Group 1 - The full subsidiary Zhejiang Huayuan Pharmaceutical Co., Ltd. has been approved for the registration of "Alpha-Lipoic Acid Tablets," which are primarily used for treating diabetic peripheral neuropathy [1] - The "Bisoprolol Amlodipine Tablets" are mainly used for the treatment of hypertension [1] - Obtaining these drug registration certificates will further enrich the company's product line and promote the upgrade of product capabilities [1]

Core Viewpoint - The report highlights the financial performance and operational strategies of North China Pharmaceutical Co., Ltd. for the first half of 2025, showcasing growth in revenue and profit despite challenges in the pharmaceutical industry [1][2]. Financial Performance - The company's operating revenue for the first half of 2025 reached approximately 5.28 billion RMB, a slight increase of 0.84% compared to the same period last year [2][10]. - Total profit amounted to approximately 214 million RMB, reflecting a significant increase of 42.68% year-on-year [2][10]. - Net profit attributable to shareholders was approximately 123.5 million RMB, up 71.56% from the previous year [2][10]. - The basic earnings per share increased to 0.072 RMB, a rise of 71.43% compared to the same period last year [2][10]. Business Overview - The company operates in the pharmaceutical manufacturing industry, focusing on the research, production, and sales of various pharmaceutical products, including antibiotics, biological drugs, vitamins, and health consumer products [3][4]. - North China Pharmaceutical has established a comprehensive product chain from raw materials to finished dosage forms, maintaining a leading position in the antibiotic sector [4][5]. Market Position and Industry Context - The pharmaceutical manufacturing industry in China is currently facing pressures such as declining profits and overall sluggish growth, with a reported 1.2% decrease in revenue for the first half of 2025 [3][6]. - Despite these challenges, the long-term outlook for the industry remains positive due to factors such as economic growth, an improving healthcare system, and increasing health awareness among the population [3][6]. Operational Strategies - The company has implemented measures to enhance efficiency and reduce costs, including centralized procurement and lean management practices [5][6]. - North China Pharmaceutical is focusing on expanding its international market presence, particularly in high-end markets like Japan, and has achieved export revenues of approximately 1.1 billion RMB in the first half of 2025 [5][6]. Research and Development - The company has increased its R&D investment to approximately 456 million RMB, representing an R&D intensity of 8.64% [6][10]. - Several new products are in the pipeline, including generic drugs and biological products, with ongoing efforts to meet consistency evaluation standards for generic drugs [6][10]. Risk Management and Quality Control - The company emphasizes strict quality control throughout the production process, ensuring compliance with national standards and maintaining a 100% pass rate in national quality inspections [7][8]. - Risk management practices have been strengthened, including regular internal audits and environmental inspections [6][8].